Related Experiment Video

Updated: Apr 10, 2026

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.9K

Role of PARP-1 in prostate cancer

Dhanraj Deshmukh1, Yun Qiu1

  • 1Department of Pharmacology, University of Maryland School of Medicine Baltimore, Maryland, 21201.

American Journal of Clinical and Experimental Urology
|June 13, 2015
PubMed

Insights

Poly (ADP-ribose) polymerase-1 (PARP-1) regulates gene expression in prostate cancer. This review explores PARP-1

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme in DNA repair.
  • PARP1 deregulation is common in various cancers, making it a therapeutic target.
  • BRCA mutations influence sensitivity to PARP inhibitors, but efficacy extends beyond these mutations.

Purpose of the Study:

  • To review the mechanisms of PARP-1 in regulating gene expression in prostate cancer.
  • To provide an overview of current clinical trials involving PARP inhibitors in cancer treatment.

Main Methods:

  • Literature review of studies on PARP-1 function in gene regulation.
  • Analysis of recent research on PARP-1's role in oncogenic signaling.
  • Compilation of data from ongoing clinical trials of PARP inhibitors.

Main Results:

  • PARP-1 plays a significant role in gene expression regulation, contributing to cancer progression.
  • Mechanisms beyond DNA repair, including transcriptional regulation, are implicated in PARP-1's oncogenic role.
  • PARP inhibitors show efficacy in a broader patient population than initially expected based on BRCA mutation status.

Conclusions:

  • PARP-1's multifaceted roles in gene expression and DNA repair are critical in prostate cancer.
  • Understanding PARP-1's regulatory functions may reveal new therapeutic strategies and patient stratification biomarkers.
  • Ongoing clinical trials are evaluating the broad potential of PARP inhibitors across various cancers.
Keywords:
PARPARP-1prostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

10.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
39.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.4K
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.4K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.3K